Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.

Yada Kanjanapan,Stephanie Lheureux,Taymaa May,Michelle K. Wilson,Marcus Q. Bernardini,Patricia Shaw,Ignace Vergote,James D. Brenton,Diane Provencher,Iain A. McNeish,Prafull Ghatage,Jonathan A. Ledermann,Nicoletta Colombo,Charlie Gourley,Johanne Weberpals,Janelle Ramsahai,Nicole Ricker,Sarah Accardi,Lisa Wang,Amit M. Oza

Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.

2017

TPS5608Background: Olaparib is a PARP inhibitor with clinical benefit in relapsed OC, especially in pts with germline BRCA1/2 mutation (gBRCA). Study 19 (NCT00753545) found a progression free survi...

Keywords:

Ovarian cancer
Pathology
Olaparib
Serous fluid
Internal medicine
Medicine
Oncology
open label
Germline
serous ovarian cancer
in patient
PARP inhibitor
platinum sensitive
multi centre

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations